Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients, a Randomized Phase II/III Study, Double-blind and Placebo-controlled

NCT05769582 is registered in ClinicalTrials.gov with Memo Therapeutics AG as lead sponsor.

NCT NCT05769582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05769582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients, a Randomized Phase II/III Study, Double-blind and Placebo-controlled
Lead sponsor
Memo Therapeutics AG
Phase
Phase 2/3
Overall status
Completed
Start date
April 10, 2023
Completion date
July 15, 2025
Enrollment
95 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

bk viremia; bkv dnaemia